[ad_1] Nov 28 (Reuters) – BioMarin Pharmaceutical (BMRN.O) said on Tuesday it will price its therapy for severe hemophilia A at 28,933.53 euros ($31,725.62) per vial for insurers covering a…
Tag: hemophilia
BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany
[ad_1] ROCTAVIAN is First Gene Therapy for Hemophilia to Receive Approved Federal Price in Germany SAN RAFAEL, Calif., Nov. 28, 2023 /PRNewswire/ — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology…
BioMarin Announces First Person Treated Commercially with ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Europe
[ad_1] First Person Treated in Germany; Reimbursement Discussions on Track in France and Italy In the U.S., ROCTAVIAN Now Commercially Available and Hemophilia Treatment Centers Have Begun Screening Eligible Individuals…
Permanent cure for hemophilia is within reach – Dr Oppong-Mensah – Ghana Business News
[ad_1] Permanent cure for hemophilia is within reach – Dr Oppong-Mensah – Ghana Business News Home General…